Background Patients with multiple endocrine neoplasia (type 1) often present with multiple pancreatic endocrine tumours, such as insulinomas. A major difficulty in the surgical treatment of such patients is identifying which tumours are functionally active and therefore need to be resected for a cure. The objective of this study was to develop a rapid insulin assay that could be used intraoperatively for identifying insulinomas from pancreatic aspirates.
Introduction
Pancreatic neuroendocrine tumours (PNETs) are derived from the beta cells of the pancreas and when functionally active can hypersecrete various hormones, such as insulin. 1, 2 Insulinoma, a type of PNET, commonly occurs in patients with type 1 multiple endocrine neoplasia (MEN1) and who often present with multiple PNETs. 1, 2 Insulinomas are usually benign but are often surgically removed in order to prevent hypoglycaemia, which can be lifethreatening. A dilemma in the surgical treatment of patients with multiple PNETs is that it is not apparent at the time of surgery which PNETs are functionally active. Because of this di¤culty, total or near total pancreatectomy has been used to treat patients with multiple PNETs. 3 However, this is a procedure with high morbidity and often requires that patients undergo lifelong treatment with insulin and/or digestive enzyme supplements. 4 The measurement of insulin by radioimmunoassay performed intra-operatively on venous blood draining the pancreas has been used to con¢rm the complete removal of insulinomas. 5 However, this procedure is not useful for identifying functionally active PNETs prior to resection. A calcium stimulation test, which involves the catheterization of the arteries of the pancreas, infusion of calcium and the measurement of insulin in samples taken from the hepatic vein, has also been used to localize insulinomas pre-operatively to either the tail, body or head of the pancreas. 6 However, it is not possible to determine the precise location of the PNETS in the pancreas by this procedure and multiple PNETs may be present at one site.
In this report, we describe the development of a rapid non-isotopic assay for insulin that can be used Short Report for monitoring the resection of insulinomas intraoperatively. We also describe a potential new application for rapid insulin assays. This involves the measurement of insulin in pancreatic aspirates, in order to identify functionally active PNETs prior to their surgical removal.
Materials and methods
The standard and rapid insulin assays were performed using a microparticle enzyme ampli¢ed £uorescence immunoassay, on an IMx analyser, using the reagents and calibrators provided by the manufacturer (Abbott Laboratories, Abbott Park IL, USA). The rapid insulin assay was run using the test parameters that were originally developed on the IMx for the stat measurement of creatine kinase MB (protocol 120). The sample volume for the rapid insulin test was increased from the standard 10 mL sample volume to 50 mL and took 14 min to perform as opposed to 35 min for the standard assay.
PNETs were identi¢ed, during surgery, by direct ultrasound of the pancreas, and samples were obtained from the tumours by ¢ne-needle aspiration using 3 mL of saline. Samples were snap-frozen on dry ice, quickly thawed under running tap water and centrifuged for 1min at 6400 g. The supernatant was serially diluted with saline to obtain 10-fold, 100-fold and 1000-fold dilutions of the samples. The undiluted supernatant £uid and all dilutions were analysed using the rapid insulin test. No matrix e¡ects were noted whether the samples were diluted with saline or the zero calibrator solution provided with the standard insulin assay kit.
Results and discussion
Because the antibody concentration in the insulin assay is in excess, the rate of the antigen^antibody reaction should be directly proportional to the antigen concentration, which is increased in the rapid assay by increasing the sample volume. An approximately fourfold increase in £uorescence signal was observed for the rapid assay (see Fig. 1a ), despite its shorter incubation time compared with the standard assay; this should facilitate the rapid measurement of low insulin concentrations.
The rapid insulin test was linear from 10 pmol/L to 2100 pmol/ L, as assessed by least square ¢t analysis (yˆ0¢969x+8; Pˆ0 ¢043; 90% con¢dence interval 0¢039^0¢047) of a serially diluted sample. The assay had an analytical detection limit (3 standard deviations above the mean of zero calibrator) of 3¢5 pmol/L (nˆ10). The intra-assay (nˆ19) and inter-assay (nˆ14) precision of the rapid insulin assay at insulin concentrations of 130 pmol/ L and 1440 pmol/L ranged from 4¢1% to 4¢7% and from 2¢8% to 7¢8%, respectively. A total of 59 serum samples with a broad range of insulin concentrations were analysed by both the standard and the rapid assay (see Fig. 1b ). The two assays showed a close correlation with each other although the rapid assay showed a proportional negative bias when compared with the standard assay.
The value of the rapid insulin assay was assessed on a 19-year-old man with a positive family history of MEN1, who was asymptomatic, except for a 1-year history of occasional lightheadedness. After a 48-h fast, he had a low plasma glucose of 1¢94 mmol/ L (3¢9^6¢4 mmol/ L) associated with an inappropriately high plasma insulin level of 174 pmol/ L (9^100 pmol/ L) and an elevated C-peptide of 1900 pmol/L (1709 00 pmol/ L). These ¢ndings are consistent with insulinoma.
Figure 1. (a) Calibration curves for the standard IMx (*) and rapid (© ) insulin assays. (b) Comparison by Deming regression of the standard IMx assay with the rapid insulin assay. MEIAˆmicroparticle enzyme immunoassay.
An abdominal computed tomography scan showed a tumour in the tail of the pancreas (PNET 1) and one in the head of the pancreas (PNET 2). Following a calcium stimulation test, only PNET 1 in the tail was suspected to be hypersecreting insulin. During surgery, direct ultrasound of the pancreas revealed two additional tumours: one in the body (PNET 3) and another in the tail (PNET 4) of the pancreas. Samples were collected by ¢ne-needle aspiration from all four PNETs and from a normal part of the pancreas and were measured for insulin by the rapid test: PNET 1 (53¢5 pmol/L), PNET 2 (804 000 pmol/L), PNET 3 (63200 pmol/ L), PNET 4 (53¢5 pmol/L), normal pancreas (57¢6 pmol/L).
PNET 3 in the body of the pancreas was excised by enucleation. Despite the undetectable insulin levels, PNETs 1 and 4 were also removed prophylactically, by enucleation, because of the apparent positive localization of a functional insulinoma in the tail following the pre-operative calcium stimulation test. PNET 2, which had the highest insulin level, was not initially resected, because its proximity to the pancreatic duct made it di¤cult to remove safely by enucleation. Its removal would have required a Whipple procedure, a complex procedure associated with high morbidity, which involves the resection of the head of the pancreas along with the duodenum and distal stomach. Post-operatively, however, there was no signi¢cant improvement in the patient's fasting glucose and insulin levels. Subsequently, the patient underwent a second operation, with the fasting glucose and insulin concentrations returning to within reference values following the removal of PNET 2. The patient has remained asymptomatic for 19 months following surgery.
Although this patient ultimately required aWhipple procedure because of the location of PNET 2, this case illustrates how the results of the rapid insulin test can potentially a¡ect the surgical approach to the management of insulinomas. The identi¢cation of functionally active PNETs by ¢ne-needle aspiration and the rapid insulin test can potentially allow their selective removal by enucleation, provided they are not too close to the pancreatic duct. This preserves enough pancreas for normal endocrine and exocrine function. Alternatively, insulinomas in the tail of the pancreas can be removed by distal pancreatectomy of the tail. Even in this case, if the results of the rapid insulin test had been fully acted upon, it would have been possible to have successfully treated the patient for hypoglycaemia during the ¢rst procedure.
In summary, the results of the rapid insulin assay compared favourably with those obtained using the standard IMx insulin assay. This assay may therefore o¡er a more practical and rapid way than previous methods 5 for the intra-operative monitoring of serum insulin levels to con¢rm the successful resection of insulinomas. More studies will be necessary to establish clinical value of the assay; however, its use in the analysis of pancreatic aspirates may also be helpful in identifying functionally active insulinomas prior to resection. This would potentially allow the surgical treatment of hypoglycaemia in MEN patients by a more simple partial pancreatectomy procedure.
